Strasbourg, France, June 29, 2015 – Transgene SA (Euronext: TNG) a biotechnology company specializing in immunotherapies for cancer and infectious diseases, announced today that it has informed the representatives of the works council of the Company’s intention to modify its vertical integration model and to implement a restructuring in order to maintain its competitiveness and to ensure a sustainable future.
Transgene intends to focus resources on its core business of research and development by advancing its clinical portfolio, reorganizing its research model, and outsourcing manufacturing and pharmaceutical development activities.
The Company will apply its resources to advancing its clinical portfolio, as well as on research and development, particularly translational research. The Company plans to continue to develop innovative immunotherapies for cancer and infectious diseases by further developing its technology platforms. The Company’s strategy is to increase collaborations with academic institutions and hospitals, as well as with biopharmaceutical partners, with partnerships occurring at an earlier stage of product development.
…
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer